# Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c

> **NCT00817739** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 341 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Leuprorelin
- **DRUG:** Flutamide

## Key facts

- **NCT ID:** NCT00817739
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-12
- **Primary completion:** 2005-09
- **Final completion:** 2008-12
- **Target enrollment:** 341 (ACTUAL)
- **Last updated:** 2015-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00817739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00817739, "Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c". Retrieved via AI Analytics 2026-09-23 from https://api.ai-analytics.org/clinical/NCT00817739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*